ZYLOX-TONBRDG.MED.TECH.H1 (818) — Net Asset Quality Index
ZYLOX-TONBRDG.MED.TECH.H1 (818) has a Net Asset Quality Index of 90.2% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €3.50 Billion minus total liabilities of €341.97 Million yields net assets of €3.15 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check ZYLOX-TONBRDG.MED.TECH.H1 (818) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
ZYLOX-TONBRDG.MED.TECH.H1 Net Asset Quality Index Over Time (2021–2024)
This chart shows how ZYLOX-TONBRDG.MED.TECH.H1's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the index stands at 90.2%, representing net assets of €3.15 Billion against total assets of €3.50 Billion EUR. See ZYLOX-TONBRDG.MED.TECH.H1 (818) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see ZYLOX-TONBRDG.MED.TECH.H1 (818) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 89.8% | €3.10 Billion | €3.45 Billion | €351.56 Million | ▼ -0.5 pp |
| 2023 | 90.3% | €3.05 Billion | €3.38 Billion | €328.32 Million | ▼ -4.8 pp |
| 2022 | 95.1% | €3.09 Billion | €3.25 Billion | €159.54 Million | ▼ -1.7 pp |
| 2021 | 96.8% | €3.14 Billion | €3.25 Billion | €103.61 Million | — |